FIA
NKTR icon

FNY Investment Advisers’s Nektar Therapeutics NKTR Stock Holding History

FNY Investment Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$383K Buy
5,500
+750
+16% +$54.9K 0.14% 176
2026
Q1 		$341K Sell
4,750
-450
-9% -$25.6K 0.15% 149
2025
Q4 		$219K Buy
5,200
+2,598
+100% +$145K 0.06% 221
2025
Q3 		$148K Buy
2,602
+1,077
+71% +$35.6K 0.05% 318
2025
Q2 		$39K Buy
+1,525
New +$17.1K 0.02% 452
2020
Q1 		– Sell
-1,120
Closed -$362K – 694
2019
Q4 		$362K Buy
1,120
+87
+8% +$25.2K 0.11% 137
2019
Q3 		$282K Buy
+1,033
New +$379K 0.09% 132

Other funds holding NKTR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
BCM
Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return
NNPTE
Nationale-Nederlanden Powszechne Towarzystwo Emerytalne Warszawa, Poland $1.83B AUM 331.52% 1-Year Est. Return
ACL
APEIRON Capital Ltd Hong Kong $156M AUM 183.17% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

FNY Investment Advisers's NKTR Position: Q2 2026 in Review

FNY Investment Advisers increased its Nektar Therapeutics (NKTR) stake by 16% in Q2 2026, buying an estimated $54.9K and bringing the position to 5,500 shares worth $383K. The position accounts for 0.14% of the portfolio, ranked #176.

FNY Investment Advisers first reported a position in NKTR in Q3 2019 and has held it in 7 quarters since. 69 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • FNY Investment Advisers held 5,500 shares of Nektar Therapeutics worth $383K as of Q2 2026.
  • FNY Investment Advisers bought 750 Nektar Therapeutics shares in Q2 2026, an estimated $54.9K.
  • Nektar Therapeutics made up 0.14% of FNY Investment Advisers's portfolio in Q2 2026, its #176 holding.
  • FNY Investment Advisers first reported a position in Nektar Therapeutics in Q3 2019 and has held it in 7 quarters since.
  • 69 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.